Acura Pharmaceuticals (STU:HD4B) Scaled Net Operating Assets: 0.23 (As of Dec. 2021)


STU:HD4B Acura Pharmaceuticals Inc STU:HD4B
16 GF Score
Price €0.20
View Full Analysis

What is Acura Pharmaceuticals Scaled Net Operating Assets?

Acura Pharmaceuticals STU:HD4B 16 Scaled Net Operating Assets is 0.23 as of Dec. 2021. GuruFocus rates STU:HD4B with a GF Score™ of 16/100.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Acura Pharmaceuticals's operating assets for the quarter that ended in Dec. 2021 was €0.70 Mil. Acura Pharmaceuticals's operating liabilities for the quarter that ended in Dec. 2021 was €0.43 Mil. Acura Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2021 was €1.20 Mil. Therefore, Acura Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2021 was 0.23.

Acura Pharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Acura Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acura Pharmaceuticals Scaled Net Operating Assets Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.12 0.19 -0.01 0.19

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.02 0.42 0.20 0.23

STU:HD4B vs VFRM, THCT, CBGL: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acura Pharmaceuticals Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's Scaled Net Operating Assets falls into.


STU:HD4B
16GF Score
Acura Pharmaceuticals Inc STU:HD4B
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acura Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Acura Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2021 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2021 )
=(Operating Assets (A: Dec. 2021 )-Operating Liabilities (A: Dec. 2021 ))/Total Assets (A: Dec. 2020 )
=(0.703-0.427)/1.427
=0.19

where

Operating Assets(A: Dec. 2021 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.761 - 0.058
=0.703

Operating Liabilities(A: Dec. 2021 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.604 - 0.148 - 0.029
=0.427

Acura Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2021 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2021 )
=(Operating Assets (Q: Dec. 2021 )-Operating Liabilities (Q: Dec. 2021 ))/Total Assets (Q: Sep. 2021 )
=(0.703-0.427)/1.195
=0.23

where

Operating Assets(Q: Dec. 2021 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.761 - 0.058
=0.703

Operating Liabilities(Q: Dec. 2021 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.604 - 0.148 - 0.029
=0.427

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.23 mean?
Acura Pharmaceuticals (STU:HD4B) has a Scaled Net Operating Assets of 0.23 as of Dec. 2021. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' Scaled Net Operating Assets too high?
Acura Pharmaceuticals' current Scaled Net Operating Assets is 0.23. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' Scaled Net Operating Assets compare to VFRM and THCT?
Acura Pharmaceuticals' Scaled Net Operating Assets of 0.23 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Acura Pharmaceuticals and its competitors. Acura Pharmaceuticals's current Scaled Net Operating Assets is 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (STU:HD4B) has a current Scaled Net Operating Assets of 0.23. The current Scaled Net Operating Assets is 0.23. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Acura Pharmaceuticals (STU:HD4B), the current Scaled Net Operating Assets is 0.23 as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acura Pharmaceuticals Business Description

Address 616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score

Get the complete analysis for STU:HD4B

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price